Skip to main content
. 2019 Feb 27;37(11):867–875. doi: 10.1200/JCO.18.01998

FIG 2.

FIG 2.

Kaplan-Meier plot of (A) progression-free survival (PFS) and (B) overall survival (OS) in patients who received NIVO3+IPI1 (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg) or NIVO1+IPI3 (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg). Symbols indicate censored observations. Median PFS was 9.92 months in the NIVO3+IPI1 group and 8.94 months in the NIVO1+IPI3 group (hazard ratio, 1.06; 95% CI, 0.79 to 1.42). Median OS was not reached in either group (hazard ratio, 1.09; 95% CI, 0.73 to 1.62).